Product Information
VERAPAMIL ER 120 MG TABLET is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.1778 per EA under NDC 75834032001. Its NADAC has been published 173 times since Jun 14, 2023.
FDA first approved this application on May 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
120 mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834032001
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VERAPAMIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206173FDA Approved
5/5/2017
TE Code
AB
On Market Since
1/2/2023
Pharmacological Classes
Price Statistics
The NADAC for VERAPAMIL ER 120 MG TABLET has been published 173 times since Jun 14, 2023, and over the history we have for it it has declined 27.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1778 per EA |
|---|---|
| All-time high | $0.2665 (Dec 13, 2023) |
| All-time low | $0.1778 (Sep 23, 2026) |
| 52-week high | $0.2492 |
| 52-week low | $0.1778 |
| Median price | $0.2185 |
| Average price | $0.2180 |
| Largest weekly change | +29.2% (Feb 21, 2024) |
| Weeks tracked | 173 |
| Tracking since | Jun 14, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 50% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Nivagen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
VERAPAMIL HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VERAPAMIL ER 120 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER 120 MG TABLET, manufactured by Nivagen Pharmaceuticals Inc., is $0.1778 per EA (NDC 75834032001), effective Sep 30, 2026.
How has the price of VERAPAMIL ER 120 MG TABLET changed over time?
Over the history we have for it, the NADAC for VERAPAMIL ER 120 MG TABLET has declined 27.8%. It has been tracked across 173 weekly CMS publications since Jun 14, 2023.
What are the highest and lowest recorded NADAC prices for VERAPAMIL ER 120 MG TABLET?
Since Jun 14, 2023, the NADAC for VERAPAMIL ER 120 MG TABLET has ranged from a low of $0.1778 (Sep 23, 2026) to a high of $0.2665 (Dec 13, 2023), with a median of $0.2185 per EA.
Are there cheaper alternatives to VERAPAMIL ER 120 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL 120 MG TABLET, is $0.0887 per EA — about 50% below VERAPAMIL ER 120 MG TABLET.
Who manufactures VERAPAMIL ER 120 MG TABLET?
VERAPAMIL ER 120 MG TABLET (NDC 75834032001) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.